Each year, the Wisconsin Alzheimer's Disease Research Center presents the Alzheimer's Disease & Related Disorders Research Day. The event is designed to encourage collaboration and promote scientific thought among faculty, students, and researchers from a wide range of disciplines across the UW-Madison campus. The event is sponsored by the Wisconsin Geriatric Education Center (WGEC).
The date for the 2019 event has not been set.
March 23, 2018
Howard J. Federoff, MD, PhD, professor of neurology at the University of California, Irvine, is a nationally renowned clinical and research leader and a groundbreaking investigator for neurological disorders. Dr. Federoff’s research discovered and validated a predictive blood test for those at risk for Alzheimer’s disease. He has been published in more than 250 peer reviewed and invited articles and serves as a reviewer for many journals, and currently serves on the editorial boards of five journals. Dr. Federoff served as chair of the NIH Recombinant DNA Advisory Committee from 2007-2010. He chairs the Gene Therapy Resource Program for NHLBI, was president for the American Society for Neural Therapy and Repair (2012-2013), and was president of the American Society for Experimental Neurotherapeutics (2014-2016). Dr. Federoff is an elected Fellow of the American Association for the Advancement of Science and the National Academy of Inventors. Prior to his arrival at UCI, Dr. Federoff was the Executive Vice President for Health Sciences and Executive Dean of the School of Medicine at Georgetown University.
June 30, 2017
Paul Aisen, MD, founding director of the University of Southern California (USC) Alzheimer’s Therapeutic Research Institute (ATRI) in San Diego, an organization with the mission to accelerate the development of effective therapies for AD. Prior to joining the USC faculty, Dr. Aisen had been professor of Neurosciences at University of California, San Diego (UCSD) School of Medicine and director of the Alzheimer’s Disease Cooperative Study from 2007 through 2015. As director of ATRI, he will be continuing his work on the development, design and implementation of multicenter trials, collaborating with academic groups and pharmaceutical companies.